EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy
Language English Country Greece Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24270553
DOI
10.3892/or.2013.2864
Knihovny.cz E-resources
- MeSH
- Gene Deletion * MeSH
- Platelet-Derived Growth Factor metabolism MeSH
- ErbB Receptors genetics MeSH
- Phosphorylation MeSH
- Gene Dosage * MeSH
- Glioblastoma genetics MeSH
- JNK Mitogen-Activated Protein Kinases biosynthesis MeSH
- Humans MeSH
- p38 Mitogen-Activated Protein Kinases biosynthesis MeSH
- Cell Line, Tumor MeSH
- Brain Neoplasms genetics MeSH
- Proto-Oncogene Proteins c-sis metabolism MeSH
- Proto-Oncogene Proteins metabolism MeSH
- Receptor, trkA metabolism MeSH
- Signal Transduction genetics MeSH
- Gene Expression Profiling MeSH
- Receptor Protein-Tyrosine Kinases metabolism MeSH
- Axl Receptor Tyrosine Kinase MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- AXL protein, human MeSH Browser
- Platelet-Derived Growth Factor MeSH
- epidermal growth factor receptor VIII MeSH Browser
- ErbB Receptors MeSH
- JNK Mitogen-Activated Protein Kinases MeSH
- p38 Mitogen-Activated Protein Kinases MeSH
- platelet-derived growth factor A MeSH Browser
- Proto-Oncogene Proteins c-sis MeSH
- Proto-Oncogene Proteins MeSH
- Receptor, trkA MeSH
- Receptor Protein-Tyrosine Kinases MeSH
- Axl Receptor Tyrosine Kinase MeSH
Epidermal growth factor receptor (EGFR) gene amplification and the overexpression of EGFR are described as common features of glioblastoma multiforme (GBM). Nevertheless, we previously reported the loss of EGFR gene copy in a GBM specimen from a patient with an unusually favorable course of the disease, and the HGG-02 cell line with this aberration was successfully derived from this tumor. Here, we present a detailed analysis of changes in gene expression and cell signaling in the HGG-02 cell line; the GM7 reference cell line with a standard EGFR gene copy number derived from a very aggressive GBM was used as a control. We confirmed the downregulation of EGFR expression and signaling in HGG-02 cells using different methods (RTK analysis, gene profiling and RT-PCR). Other changes that may have contributed to the non-aggressive phenotype of the primary tumor were identified, including the downregulated phosphorylation of the Axl and Trk receptors, as well as increased activity of JNK and p38 kinases. Notably, differences in PDGF signaling were detected in both of these cell lines; HGG-02 cells preferentially expressed and signaled through PDGFRα, and PDGFRβ was strongly overexpressed and phosphorylated in the GM7 reference cell line. Using expression profiling of cancer-related genes, we revealed the specific profile of HGG-02 cells that included upregulated tumor-suppressors as well as downregulated genes associated with the extracellular matrix. This study represents the first comprehensive analysis of gene expression and cell signaling in glioblastoma cells with lower EGFR gene dosage. As indicated by our results, the TAM receptors, Trk receptors and PDGFRs need to be investigated further since their regulation appears to be important for glioblastoma biological features as well as the clinical course of the disease.
References provided by Crossref.org